7th Annual Advances in Managing Diseases of the CNS: MS & PD
Venue: Hermitage Hotel
|Event Date/Time: Nov 08, 2008||End Date/Time: Nov 09, 2008|
Treatment of MS focuses on relapse management, symptomatic therapies, and altering the long-term course of the disease. While significant gains have been made in our understanding of MS in the past 15 years, many challenges remain. As attention has shifted towards disease modification, we sometimes neglect options for improving quality of life now. Combined with the clinical presentation, MRI has been a valuable diagnostic tool for MS.
MRI metrics are commonly included in MS trials. Questions remain regarding how to best use MRI in the long term management of MS. It is hoped that newer MRI modalities may prove to have better correlation with disease progression than current options. The quieting effect of pregnancy on MS has long pointed towards some role for sex hormones in MS. What are the factors involved in pregnancy and the post-partum period that affect MS?
What effect do menses and the perimenopause have on MS? Is there therapeutic potential for sex hormones in MS? Finally, recent trials have compared some of the existing disease modifying therapies. What are the strengths and weakness of these trials and what have we learned from them? What therapies may be on the horizon for MS?
Parkinson's Disease (PD) is the most common of the major movement disorders, a category of conditions in which a malfunction in the nervous system affects communication between the brain and the muscles. PD is a chronic, progressive neurological disorder that was called â€œshaking palsyâ€ when it was first described by James Parkinson in 1817. It may be difficult to diagnose in the early stages because the symptoms begin gradually and progress over time.
According to the NIH, Parkinsonâ€™s affects at least 500,000 people in the US, and some estimates put the number much higher; the Parkinsonâ€™s Disease Foundation estimates that as many as 1 million people are affected. Some 50,000 cases are diagnosed each year, a number that is expected to rise as the population ages. Most cases begin between the ages of 50 and 65, with the average age of onset about 60â€”though younger people are affected, too.
This program will focus on the identification and management of motor and non-motor features of PD.